rs9277535 — HLA-DPB1

3' UTR eQTL that reduces HLA-DPB1 expression, impairing antigen presentation and increasing risk for chronic hepatitis B infection; also linked to multiple sclerosis and modulates rheumatoid arthritis risk through a dose-dependent trade-off in immune activation

See your personal result for HLA-DPB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HLA-DPB1 rs9277535 — The Antigen Presentation Rheostat

HLA-DPB1 encodes the beta chain of the HLA-DP molecule, a class II MHC receptor that presents peptide antigens to CD4+ T helper cells. This is the essential handshake that triggers adaptive immunity: without robust HLA-DP surface expression, the immune system cannot efficiently recognize viral peptides and mount a clearance response. The rs9277535 variant sits in the [3' untranslated region (3' UTR) | The regulatory sequence at the end of the mRNA transcript that controls stability, translation efficiency, and expression level — not the protein-coding region itself] of HLA-DPB1 and acts as an [eQTL | expression quantitative trait locus — a variant whose primary effect is on how much gene product is made rather than what kind] controlling transcript levels. The G allele substantially reduces HLA-DPB1 mRNA, shifting the antigen presentation dial downward.

The Mechanism

The rs9277535 G allele lies in the 3' UTR of HLA-DPB1 transcript NM_002121.6 and is in [linkage disequilibrium | Alleles at nearby positions that tend to be inherited together more often than expected by chance, so rs9277535 G tags a broader haplotype block] with functionally connected variants across the HLA-DP locus. Expression studies confirmed that the GG genotype is associated with the lowest HLA-DPB1 mRNA levels11 GG genotype is associated with the lowest HLA-DPB1 mRNA levels
p=10⁻¹⁵ in 651 normal liver samples; allelic expression imbalance analysis in 17–19 heterozygotes confirmed the G allele produces less transcript than the A allele across liver tissue. Lower surface HLA-DPB1 expression translates directly to fewer antigen-presenting molecules available to engage virus-derived peptides and activate CD4+ T helper cells.

The consequence is a classic MHC trade-off: reduced HLA-DPB1 expression limits the risk of excessive immune activation (relevant to autoimmune conditions), but also limits the immune system's capacity to clear intracellular pathogens that depend on CD4+ T helper responses for viral elimination. This tension explains why rs9277535 simultaneously influences risk in opposite directions for viral infections and certain autoimmune diseases.

The Evidence

Hepatitis B clearance provides the most robustly replicated phenotype. A study of 200 Taiwanese chronic HBV patients compared those who spontaneously [cleared HBsAg | Hepatitis B surface antigen — its disappearance from blood marks functional cure of chronic infection] against persistent carriers, finding the non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)22 non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)
Cheng et al. 2013, PLoS One; haplotype analysis combining rs3077 and rs9277535 strengthened the OR to 2.17. Replication in an Indonesian cohort of 686 participants confirmed a protective association across a South-East Asian population (OR 0.70 additive model, P=0.026)33 (OR 0.70 additive model, P=0.026). The underlying molecular mechanism — reduced HLA-DPB1 expression in risk allele carriers — was mechanistically established in liver eQTL analysis, directly linking the expression deficit to the antigen presentation failure that allows HBV to persist (O'Brien et al. 2011, Genes & Immunity)44 (O'Brien et al. 2011, Genes & Immunity).

Autoimmune disease associations reveal the other side of the trade-off. In multiple sclerosis, rs9277535 shows an independent genome-wide significant association with susceptibility (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls)55 (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls) driven by the correlation with HLA-DPB1*03:01 — a specific protein allotype linked to MS in earlier candidate-gene studies. For rheumatoid arthritis, the picture reflects the expression axis clearly: in Chinese Han patients, the A allele (higher HLA-DPB1 expression) was associated with increased RA susceptibility (OR 1.409, P=0.004; 254 RA cases, 391 controls)66 (OR 1.409, P=0.004; 254 RA cases, 391 controls) and elevated anti-CCP antibodies, while the G allele (lower expression) was protective77 G allele (lower expression) was protective
OR for protective effect confirmed in 805 RA patients vs 1,095 controls; AG and GG genotypes associated with lower plasma HLA-DPB1 levels. This inverse relationship — the same allele that reduces HBV clearance reduces RA risk — is the hallmark of [balancing selection | Evolutionary pressure maintaining both alleles in a population because heterozygotes have an advantage over either homozygote, common in MHC genes exposed to conflicting infectious and autoimmune pressures] at the MHC locus.

Practical Actions

The G allele's primary actionable consequence is impaired HBV clearance capacity. GG homozygotes have lower HLA-DPB1 surface expression, producing a weaker CD4+ T helper response to hepatitis B antigens. This translates to reduced natural clearance after HBV exposure and, importantly, reduced vaccine response — HBV vaccine efficacy depends on the same antigen presentation machinery this variant diminishes. AA individuals who carry two copies of the higher-expression A allele have efficient antigen presentation but carry elevated susceptibility to autoimmune conditions like RA in populations where this trade-off is clinically relevant.

The G allele is substantially more common in East Asian populations (~62% allele frequency vs ~24% in Europeans), which aligns with the higher burden of HBV chronic infection in East Asian countries and the known population-stratified effects of HLA-DP variants on HBV outcomes. Because G allele carriers may mount suboptimal vaccine responses, verifying seroconversion after HBV vaccination is a specific, genotype-informed recommendation.

Interactions

rs9277535 interacts with rs3077 (in the 3' UTR of the neighboring HLA-DPA1 gene) to form a combined HLA-DP haplotype. The GA haplotype (rs3077 G + rs9277535 A) showed a stronger association with HBV clearance than either SNP alone (OR 2.17 vs 1.83 for rs9277535 alone). The two SNPs co-regulate the HLA-DPA1/DPB1 heterodimer — the functional antigen presentation unit — meaning that variation in both alpha and beta chains together determines the overall antigen presentation phenotype. The nearby rs9277534 (496A/G) tags a different haplotype block with partially overlapping effects. For a comprehensive HLA-DP antigen presentation assessment, both rs3077 and rs9277535 should be interpreted together.

Genotype Interpretations

What each possible genotype means for this variant.

AA High Antigen Presenter Normal

Full HLA-DPB1 expression; robust antigen presentation and efficient hepatitis B immune response

You carry two copies of the A allele at rs9277535, associated with the highest HLA-DPB1 mRNA and surface protein levels. Your immune cells express robust levels of HLA-DP antigen-presenting molecules, supporting efficient CD4+ T helper cell activation against viral peptides including hepatitis B surface antigens. This is the predominant global genotype, carried by approximately 56% of people worldwide. In East Asian populations, this genotype is less common (~14%), while among Europeans it occurs in roughly 58% of individuals.

AG Intermediate Antigen Presenter Intermediate

One copy of the low-expression allele; moderately reduced HLA-DPB1 levels with slightly decreased hepatitis B clearance capacity

Heterozygous AG individuals carry one copy of the lower-expression G haplotype and one copy of the higher-expression A haplotype. Expression studies in liver tissue showed a clear dose-response relationship: GG carriers have the lowest expression, AG intermediate, and AA the highest. The allelic expression imbalance confirmed at the molecular level that the G allele transcript is present at lower levels than the A allele transcript in the same cell. For HBV outcomes, the effect is additive — each additional G allele modestly reduces clearance probability. Post-vaccination serology is valuable to confirm that protective anti-HBs titers were achieved, as the HBV vaccine depends on the same HLA-DP antigen presentation machinery this variant reduces.

GG Reduced Antigen Presenter Reduced

Two copies of the low-expression allele; substantially reduced HLA-DPB1 expression and impaired hepatitis B antigen presentation

The GG genotype sits at the low end of the HLA-DPB1 expression range. Expression quantitative trait locus (eQTL) analysis in 651 liver samples established that rs9277535 is one of the strongest cis-eQTLs for HLA-DPB1 expression, with a p-value of 10⁻¹⁵. The GG genotype showed significantly lower mRNA than the AG or AA genotype in a dose-dependent fashion. Allelic expression imbalance analysis in heterozygous individuals confirmed that the G allele transcript is intrinsically produced at lower levels, ruling out a purely confounding haplotype effect.

The functional consequence for HBV is direct: HLA-DP molecules must present viral peptides derived from HBsAg, HBcAg, and HBeAg to naïve CD4+ T cells, which then coordinate the neutralizing antibody response (via B cell help) and cytotoxic T cell (CD8+) licensing needed for viral clearance. Fewer HLA-DP surface molecules mean fewer antigen-peptide complexes displayed, a weaker T helper response, and a higher probability that low-level HBV replication persists unchecked. This mechanism directly predicts both natural infection persistence and reduced HBV vaccine efficacy in GG carriers.

For RA, the picture inverts: lower HLA-DPB1 expression reduces the immune activation that drives RA in some East Asian populations, meaning GG carriers may have modestly lower RA susceptibility — a direct reflection of the MHC balancing selection trade-off.